Recurrent Malignant Glioma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Recurrent Malignant Glioma - Pipeline Review, H1 2015', provides an overview of the Recurrent Malignant Glioma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Recurrent Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Recurrent Malignant Glioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Recurrent Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Recurrent Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Malignant Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Malignant Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Recurrent Malignant Glioma Overview 6 Therapeutics Development 7 Pipeline Products for Recurrent Malignant Glioma - Overview 7 Pipeline Products for Recurrent Malignant Glioma - Comparative Analysis 8 Recurrent Malignant Glioma - Therapeutics under Development by Companies 9 Recurrent Malignant Glioma - Therapeutics under Investigation by Universities/Institutes 10 Recurrent Malignant Glioma - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Recurrent Malignant Glioma - Products under Development by Companies 13 Recurrent Malignant Glioma - Products under Investigation by Universities/Institutes 14 Recurrent Malignant Glioma - Companies Involved in Therapeutics Development 15 Amgen Inc. 15 AstraZeneca PLC 16 Eisai Co., Ltd. 17 Nerviano Medical Sciences S.r.l. 18 Sanofi 19 Recurrent Malignant Glioma - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 cabazitaxel - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Carboxyamidotriazole Orotate - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 carmustine SR - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Cell Therapy for Refractory Gliomas - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Cell Therapy to Target IL-13 for Malignant Glioma - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Dendritic Cell Therapy for Metastatic Melanoma and Recurrent Malignant Glioma - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Dendritic Cell Therapy for Oncology - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 disufenton sodium - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 DNX-2401 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 lenvatinib - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 milciclib - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 rilotumumab - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Recurrent Malignant Glioma - Recent Pipeline Updates 51 Recurrent Malignant Glioma - Dormant Projects 56 Recurrent Malignant Glioma - Discontinued Products 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 59 Disclaimer 59
List of Tables Number of Products under Development for Recurrent Malignant Glioma, H1 2015 7 Number of Products under Development for Recurrent Malignant Glioma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Recurrent Malignant Glioma - Pipeline by Amgen Inc., H1 2015 15 Recurrent Malignant Glioma - Pipeline by AstraZeneca PLC, H1 2015 16 Recurrent Malignant Glioma - Pipeline by Eisai Co., Ltd., H1 2015 17 Recurrent Malignant Glioma - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 18 Recurrent Malignant Glioma - Pipeline by Sanofi, H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Recurrent Malignant Glioma Therapeutics - Recent Pipeline Updates, H1 2015 51 Recurrent Malignant Glioma - Dormant Projects, H1 2015 56 Recurrent Malignant Glioma - Discontinued Products, H1 2015 57
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.